These advancements could revolutionize diagnosis and treatment for patients facing this challenging condition. Systemic mastocytosis (SM) is characterized by an abnormal accumulation of mast cells ...

This article will provide a comprehensive understanding of ISM, highlighting its distinct features, causes, diagnosis, ...

The company’s primary revenue driver, Ayvakit, has been approved for the treatment of indolent systemic mastocytosis (ISM) and advanced systemic mastocytosis (ASM), positioning Blueprint at the ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

Blueprint Medicines Corporation (NASDAQ:BPMC), a commercial-stage biotech firm with a market capitalization of $5.8 billion specializing in precision therapies for rare diseases, has been making ...

Blueprint Medicines Corporation (NASDAQ:BPMC), currently valued at $5.78 billion, has been making significant strides in the precision therapy market, particularly with its flagship drug Ayvakit for ...

The clinical results presented at AAAAI 2025 focus on the patients from the OLE who have received treatment with the recommended Phase 2 dose of 100 mg bezuclastinib ... signs of clinical activity ...